SOLV Stock Recent News

2024 was quite a year for Nelson Peltz's hedge fund, Trian Fund Management.

Solventum's fourth-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.

Diversified healthcare company Solventum (SOLV -0.71%) reported fourth-quarter 2024 earnings on Thursday, Feb. 27, that topped analysts' consensus estimates. Adjusted EPS for the quarter came in at $1.41 against an anticipated $1.31 and revenue of $2.074 billion exceeded the expected $2.050 billion.

Solventum Corporation (NYSE:SOLV ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations and External Finance Communications Bryan Hanson - Chief Executive Officer Wayde McMillan - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler & Co. Patrick Wood - Morgan Stanley David Roman - Goldman Sachs Group, Inc. Travis Steed - Bank of America Vikramjeet Chopra - Wells Fargo Securities Frederick Wise - Stifel, Nicolaus & Company, Inc. Operator Good afternoon. My name is Ellie, and I will be your conference call operator today.

3M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.

Reported sales increased 1.9% to $2.074 billion; organic sales increased 2.3% GAAP diluted Earnings Per Share (EPS) of $0.17; adjusted EPS1 of $1.41 Generated $219 million in cash from operations; free cash flow of $92 million Introduces full-year 2025 organic sales growth, adjusted EPS and free cash flow guidance ST. PAUL, Minn.

Learn more about Solventum's long-term strategy to accelerate growth Join in person or via virtual webcast ST. PAUL, Minn.

Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum for further business separations following the company's $4.1 billion filtration unit sale, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) (“Solventum” or the “Company”) and is the Company's largest active shareholder, commented on Solventum's recently announced sale of its Purification & Filtration business to Thermo Fisher Scientific Inc (NYSE: TMO) (“Thermo Fisher”). Trian issued the following statement:

Solventum In The Early Stages Of A Multiyear Turnaround Effort